Citations

Clear

6729 citation(s) found for "Li, Mark".

Recommendations for the Deprescribing of Psychotropic Medications
Goldberg, Joseph F. , McIntyre, R. S., Freeman, Marlene P. , Mago, Rajnish, Citrome, Leslie, Rosenblat, Joshua D., Thase, Michael E., Tohen, Mauricio, Vieta, Eduard, Malhi, Gin S, Sajatovic, M., Shelton, Richard C. , Macaluso, Matthew , Berk, Michael, Perlis, Roy H., Ostacher, Michael J., Khan, Arifulla, Sanacora, Gerard , Kane, John M., D, Goodman, Nierenberg, Andrew A., Correll, Christoph U., Kupka, R. W., Kasper, Siegfried, Furukawa, Toshi A., Davis, Lori L., Aaronson, Scott T., Gitlin, Michael , Jha, Manish K., Cohen, Lawrence J. , Papakostas, George I. , Mitchell, Philip B., Gorwood, P., Gupta, Swapnil , Frye, Mark A., Young, A. H., Zohar, Joseph, Steingard, Sandra , Zarate, Carlos A., Clayton, Anita H. , Shelton, Richard C. , Young, Allan H. , Ostacher, Michael J. , Jha, Manish K. , Young, Allan H , Jha, Manish K , Ostacher, Michael J , McIntyre, Roger S. , Swartz, Holly A. , Citrome, Leslie , Rosenblat, Joshua D. , Thase, Michael E. , Tohen, Mauricio , Vieta, Eduard , Malhi, Gin S. , Sajatovic, Martha, Berk, Michael , Perlis, Roy H , Iosifescu, Dan Vlad , Rubio, Jose M , Kane, John M. , Nierenberg, Andrew A. , Correll, Christoph Ulrich , Kupka, Ralph , Kasper, Siegfried , Furukawa, Toshi A , Aaronson, Scott T. , Mitchell, Philip B , Gorwood, Philip , Frye, Mark A. , Zohar, Joseph , Zarate, Carlos A.

Mayo Clinic

JAMA Network Open | February 25, 2026 | Volume: 9 | Issue: 2 | Pages: e260043

10.1001/jamanetworkopen.2026.0043 | PMID 41739481 Get It

Importance There is a need for greater recognition of clinical psychopharmacology endpoints, including instances where specific psychotropic medications may become unnecessary, redundant, contradictory, or otherwise inappropriate and therefore merit deprescribing. Objective To address circumstances warranting psychotropic medication deprescribing. Evidence Review The American Society of Clinical Psychopharmacology convened a panel of 45 international psychopharmacology experts who developed and completed a multiround Delphi survey and conducted a focused literature review between January and May of 2025, in order to identify areas of consensus or disagreement on key aspects of the deprescribing of psychotropic medications. These included collaborative risk-benefit assessments with patients; pharmacokinetic and pharmacodynamic factors; pharmacogenomics; distinguishing redundant or conflictual from complementary mechanisms of action; managing adverse effects; assuring medication adherence; drug tolerance or tachyphylaxis; medication misuse; and the psychological context and ramifications of deprescribing. Findings Consensus was achieved on 44 of 50 final Delphi statements (88%). Panelists unanimously agreed that components of a pharmacotherapy regimen should undergo periodic review to ensure that treatments target relevant symptoms and have favorable risk-benefit ratios. Key points of consensus were that deprescribing: (1) should not occur without first assessing medication adherence; (2) merits consideration if less than partial therapeutic response is apparent, or if treatment goals have been reached and relapse prevention is not a long-term objective; (3) involves psychological ramifications that warrant attention; (4) should be followed by close clinical monitoring; and (5) risk-benefit decisions should ideally involve active patient participation within a shared decision-making model. Conclusions and Relevance Through this Consensus Statement, the Task Force identified circumstances in which the selective elimination of certain psychotropic medications may be clinically indicated. Empirical trials are needed to assess the implementation of deprescribing protocols and gauge their safe, effective, and acceptable outcomes.
Factors associated with subjective cognitive complaints in former American football players
Adler, Jennifer S. , Yhang, Eukyung , Tripodis, Yorghos, Adler, Charles H., Balcer, Laura J. , Bernick, Charles, Ashton, Nicholas, Zetterberg, Henrik, Blennow, Kaj, Peskind, Elaine, Banks, Sarah J., Barr, W, Wethe, Jennifer V. , Bondi, Mark W., Delano-Wood, Lisa, Cantu, Robert C., Coleman, Michael J., Dodick, David W., Daneshvar, Daniel H., McClean, M M, Mez, Jesse, Palmisano, Joseph N., Martin, Brett, Lin, Alexander P., Bouix, Sylvain, Cummings, Jeffrey L., Shenton, Martha E., Reiman, Eric M., Stern, Robert A., Alosco, Michael L. , Alosco, Michael L , Wethe, Jennifer V , Ly, Monica T. , Tripodis, Yorghos , Adler, Charles H. , Bernick, Charles , Blennow, Kaj , Peskind, Elaine R. , Banks, Sarah J. , Barr, William , Bondi, Mark W. , Delano‐Wood, Lisa , Cantu, Robert C. , Coleman, Michael J. , Dodick, David W. , Daneshvar, Daniel H. , McClean, Michael D , Mez, Jesse , Palmisano, Joseph , Koerte, Inga K , Bouix, Sylvain , Cummings, Jeffrey L. , Shenton, Martha E. , Reiman, Eric M.

Mayo Clinic

Journal of the International Neuropsychological Society | February 25, 2026 | Volume: 32 | Issue: 2 | Pages: 132-146

10.1017/s1355617726101866 | PMID 41738687 Get It

Abstract Objective: Subjective cognitive complaints (SCC) can precede cognitive decline and are associated with demographic, exposure, lifestyle, and psychological factors. Prevalences of SCC and their correlates in individuals with repetitive head impacts (RHI) are poorly understood. This study characterized SCC in former elite American football players by frequency, mood and behavioral correlates, concordance with informant reports, and associations with neuropsychological test performance, cerebrospinal fluid (CSF), and magnetic resonance imaging (MRI) markers of neurodegeneration. Method: Former American football players ( n = 180) completed measures of global and domain-specific SCC, neuropsychiatric symptom questionnaires, neuropsychological testing, lumbar puncture, and MRI. Elastic net regression evaluated the relative importance of potential SCC correlates. Intraclass correlation coefficients measured concordance between self and informant reports. Multiple linear regressions tested associations between SCC and verbal memory and executive functioning scores. CSF Aβ 1-42 , p-tau 181 , t-tau, neurofilament light (NfL), hippocampal volume, and regional cortical thickness were examined for their potential associations with SCC. Results: Rates of SCC ranged from 43 to 77% depending on the domain. Symptoms of depression, impulsivity, and anxiety were strongly associated with SCC. Self- and informant-reported SCC showed moderate inter-rater agreement. Adjusting for age, race, education, APOE ϵ4 carrier status, and depressive symptoms, SCC were associated with lower objective verbal memory and executive functioning performance. SCC were associated with lower parahippocampal cortical thickness but not with hippocampal volume or any of the measured CSF tests. Conclusions: SCC are strongly associated with neuropsychiatric factors in former American football players. SCC may also be a marker of cognitive decline and neurodegeneration.
Morphological set enrichment enables interpretable prognostication and molecular profiling of meningiomas
Ayad, Marina A. , McCortney, Kathleen, Congivaram, Harrshavasan , Hjerthen, Mateo Gomez, Steffens, Alicia , Youngblood, Mark W., Heimberger, Amy B. , Chandler, James P., Jamshidi, Pouya, Magill, Stephen T., Raleigh, David R., Horbinski, Craig M., Cooper, Lee , McCortney, Kathleen , Jamshidi, Pouya , McCortney, Kathleen , Chandler, James P. , Zhang, Heng , Youngblood, Mark W. , Heimberger, Amy B. , Ahrendsen, Jared T. , Magill, Stephen T. , Raleigh, David R. , Horbinski, Craig , Gomez, Mateo

Mayo Clinic

No container title available | February 25, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.02.23.26346491 Get It

ABSTRACT Meningiomas are the most common primary brain tumors and, despite their benign reputation, often behave aggressively. Meningiomas are morphologically heterogeneous, yet the full significance of their histologic diversity is unclear. This is in large part because many features are not readily quantifiable by traditional observer-based light microscopy. Molecular testing improves prognostic stratification, but is not universally accessible. We therefore sought to determine whether an artificial intelligence (AI)-trained program could predict specific genomic and epigenomic patterns in meningiomas, and whether it could extract more prognostic information out of standard hematoxylin and eosin (H&E) histopathology than the current WHO classification. To do this, we developed Morphologic Set Enrichment (MSE), an interpretable computational pathology framework that quantifies statistical enrichment of morphologic patterns, cells, and tissue architecture from H&E whole-slide images. The MSE meningioma histology program was able to accurately predict DNA methylation subtypes and concurrent chromosome 1p/22q losses, in the process identifying specific morphologic patterns associated with key genomic and epigenomic alterations. It also added prognostic value independent of standard clinical and pathological variables. These results demonstrate that AI-based quantitative morphologic profiling can capture clinically and biologically relevant information that redefines risk stratification for meningiomas, incorporating histological information not included in existing grading schemes.
Feasibility of decentralized real-world monitoring of SARS-CoV-2 booster vaccines and COVID-19 outcomes in myeloma
Wood, William A, Kumar, Shaji K, Semmel, Emily, James, Shandra, Chung, David J., Rosenberg, Aaron S., Zonder, Jeffrey A. , Rubinstein, Samuel M., D'Souza, A, Martin, Thomas, Chari, Ajai, Vij, Ravi, Nooka, Ajay K., Anderson, Kenneth C., NEUBERG, D, Torres, Kathleen, Weiss, Brendan M. , Pederson, Levi , Geyer, Susan, Usmani, Saad Z., Wood, William A. , D’Souza, Anita , Rosenberg, Aaron S. , Wood, William A , Kumar, Shaji K , Chung, David J , Rosenberg, Aaron , D'Souza, Anita , Pederson, Levi D , Derkach, Andriy , Kumar, Shaji , Semmel, Emily A., Schroeder, Mark A. , Rubinstein, Samuel M. , Martin, Thomas, Nooka, Ajay K. , Anderson, Kenneth C., Neuberg, Donna , Richard, Shambavi , Torres, Kathleen, Derkach, Andriy , Usmani, Saad Z.

Mayo Clinic

Blood Advances | February 24, 2026 | Volume: 10 | Issue: 9 | Pages: 3094-3102

10.1182/bloodadvances.2025018963 | PMID 41734388 Get It

Abstract Patients with multiple myeloma have an elevated risk of severe complications from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; COVID-19) infection. To demonstrate proof of concept for a pandemic preparedness and response network, the American Society of Hematology Research Collaborative Multiple Myeloma Program developed a prospective, decentralized study within a site-based provider network. In the COVID-19 outcomes in myeloma and the impact of vaccines (COSMIC) study, patients provided consent, permitted electronic health record data collection, completed patient-reported outcomes at baseline, day 30, and day 180 through an electronic study portal, and were compensated for participation. Clinicians at participating sites facilitated study recruitment and shared best practices monthly to accelerate study execution. The COSMIC study rapidly consented 201 patients from 8 participating sites over 4 months (22 January 2024 through 17 May 2024). Consented participants were 30 to 93 years old, with a median age of 67; 46% were female, 69% were non-Hispanic White, 17% were non-Hispanic Black, and 8% were Hispanic/Latino. Patient-reported data completion was 97% at baseline, 81% at 1 month, and 79% at 6 months. At baseline, 55% of patients reported a history of COVID-19 infection and had received a median of 4 SARS-CoV-2 vaccines. For all patients, there were an additional 18 COVID-19 infections and 57 vaccines received during the 6-month observation period. There were no significant differences in health-related quality of life over time or by history of COVID-19 infection. COSMIC demonstrates the feasibility of an innovative evidence generation strategy to drive rapid accrual of patients to address an evolving area of need. This trial was registered at www.clinicaltrials.gov as #NCT05831787.
Characterization of adrenal masses in young adults at a tertiary care academic medical center
Jacob, Sarah A. , Hoegger, Mark J. , Ludwig, Daniel R. , Pandian, T K, Santos, Claudia Villatoro, Brunt, L M, Bancos, Irina, Genere, Natalia , Jacob, Sarah , Bancos, Irina , Genere, Natalia , Itani, Malak , Bancos, Irina

Mayo Clinic

Journal of the Endocrine Society | February 24, 2026 | Volume: 10 | Issue: 5 | Pages: No page available

10.1210/jendso/bvag043 | PMID 41982342 Get It

Abstract Context Evidence on the etiology and function of adrenal masses in younger adults is scarce. Objective This work aimed to characterize the clinical, imaging, and biochemical presentation of adrenal masses in 18- to 40-year-olds. Methods A retrospective cohort study was conducted January 2016 to December 2021 at a tertiary academic medical center. Participants included young adults (age 18-40 years) with adrenal masses identified through radiologic registry. Exclusion criteria included preexisting adrenal masses before 2016, hyperplasia, or masses smaller than 1 cm. Outcomes included adrenal mass diagnosis, as determined by reference standard of histopathology, radiologic surveillance, and biochemical evaluation. Results A total of 255 patients (women 142 [56%]; White 156 [61%]; median age 35 years [interquartile range 30-39 years]) were included. Comorbidities included genetic predisposition syndromes (16, 6.3%), preexisting malignancy (70, 27%), obesity (100, 48%), hypertension (89, 35%), and diabetes (25, 10%). The majority of adrenal masses were incidentally found (184, 72%) and median size was 1.9 cm (IQR 1.4-2.7 cm) on detection. Among adrenal masses in young adults, prevalence of malignancy and pheochromocytoma was 16% and 4%, respectively; among adrenal incidentalomas, 5% were malignant. Factors associated with malignancy or pheochromocytoma in multivariable analysis included nonincidental mechanism of discovery (odds ratio [OR] 15.5; 95% CI, 7.2-35.7; P < .001), and larger size (OR 1.5; 95% CI, 1.2-2.0; P < .001). Hormonal evaluation was performed in only 57 (22%) patients and was positive for hormone hypersecretion in 16 (28%) of tested individuals. Conclusion We demonstrated a high prevalence of malignancy and pheochromocytoma in our cohort of young adults with adrenal masses. Completion of appropriate hormonal work-up was infrequent, potentially missing patients with functioning adrenal adenomas.
Fisetin-Mediated Topical Modulation of Senescent Cells in Skin Improves Wound Healing Dynamics in Diabetic Mice
Numani, Asfia , Carrasco-Jeldres, Margarita, Hernandez-Rovira, Barbara B., Purushothaman, K‐Raman , Melin, M. Mark , Kirkland, James L., Wyles, Saranya P. , Numani, Asfia , Hernandez-Rovira, Barbara, Melin, Matthew M , Wyles, Saranya, Kirkland, James L.

Mayo Clinic

Advances in Wound Care | February 24, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/21621918261426580 | PMID 41730842 Get It

Objective: Diabetes mellitus affects over 25% of adults aged 65+ in the United States and is associated with a heightened risk of developing diabetic foot ulcers. Accumulation of senescent cells within the wound microenvironment can impair cutaneous repair, and senolytic therapies offer a promising approach to accelerate wound healing. Approach: In this study, topical fisetin, a flavonoid that promotes apoptosis of senescent cells, was evaluated for its impact on diabetic wound repair. Full-thickness excisional wounds were created on the dorsal skin of diabetic (db/db) mice. Animals were randomized to receive either topical vehicle ( n = 12) or fisetin ( n = 12) for three consecutive days per week, and wound healing outcomes were longitudinally assessed. Results: Topical fisetin significantly increased the ratio of healthy dermis to granulation by day 7 ( p = 0.04) and reduced dermal fibrosis by day 21 ( p = 0.03). Fisetin decreased p16+ cells ( p = 0.01) but increased p21+ cells ( p = 0.02) at day 7 in the dermis, indicating varied effects on senescent cells. M1 macrophages (CD80+) were decreased in the fisetin-treated group ( p = 0.05) at day 21, accompanied by a decrease in pro-inflammatory senescence-associated secretory phenotype cytokines, tumor necrosis factor alpha ( p = 0.03), and interleukin-1beta ( p = 0.01) at day 7. Innovation: Fisetin is the first topical seno-modulatory agent shown to enhance wound repair when administered after injury onset. Its favorable safety and efficacy in both modulating senescence and inflammation highlight its potential as a novel therapy for diabetic wounds. Conclusion: Topical fisetin enhances diabetic wound healing by reducing fibrosis and promoting healthy dermal regeneration through senescence and inflammation modulation. Saranya Wyles, MD, PhD
Sodium-glucose cotransporter-2 inhibitors lower risk of kidney replacement therapy and mortality in bipolar disorder with chronic kidney disease
Singh, Balwinder, Suarez, Maria L. Gonzalez, Baweja, Ritika, Abulseoud, Osama A. , Saunders, Erika F.H., Frye, Mark A., Baweja, Raman , Singh, Balwinder , Singh, Balwinder , Abulseoud, Osama A , Baweja, Ritika , Saunders, Erika F.H. , Frye, Mark A.

Mayo Clinic

Therapeutic Advances in Psychopharmacology | February 20, 2026 | Volume: 16 | Issue: No issue available | Pages: No page available

10.1177/20451253261423437 | PMID 41732711 Get It

Background: Bipolar disorder (BD) is associated with a higher prevalence of chronic kidney disease (CKD) and increased mortality, yet individuals with both BD and CKD are less likely to receive kidney replacement therapy (KRT). Sodium-glucose cotransporter-2 inhibitors (SGLT2is) provide renal protection in diabetes, but their long-term effects in this high-risk population remain unknown. Objectives: To evaluate whether SGLT2i use reduces the risk of KRT and all-cause mortality in adults with BD and mild-to-moderate CKD (stage ⩽ 3). Design: Observational cohort study with propensity score matching (PSM). Method: In this study using TriNetX (2009–2024) real-world database, 89,369 adults with BD and mild-to-moderate CKD were classified as SGLT2i users ( n = 12,736) or nonusers ( n = 76,633). Primary outcomes were progression to KRT and all-cause mortality over 5 years. Adjusted hazard ratios (aHRs) were estimated using Cox proportional hazards models, and 1:1 PSM reduced confounding. Subgroup analyses examined sex, race/ethnicity, diabetes status, CKD stage, and mood stabilizer use. Results: SGLT2i use was associated with lower risk of KRT (aHR 0.47 (95% CI, 0.42–0.53)) and all-cause mortality (aHR 0.69 (95% CI, 0.65–0.73); both p < 0.001). Protective effects were consistent across subgroups, including individuals receiving lithium, lamotrigine, valproate, or antipsychotics. After PSM (10,967 matched pairs), 5-year KRT-free survival was 94.61% versus 90.99%, and overall survival was 78.67% versus 67.53% (both p < 0.001). Given the observational design, the possibility of residual or unmeasured confounding canot be excluded. Conclusion: SGLT2i therapy in individuals with BD and mild-to-moderate CKD is associated with substantially lower risks of KRT and all-cause mortality. Prospective trials are needed to confirm these findings.
Abstract PS2-07-27: Qutils: open-source image-based infiltrating immune cell detection and outcomes in calgb 40502, calgb 40603, and calgb 40601 phase iii breast cancer clinical trials
Vater, Mark, Salgado, Roberto , Blige, E., LeFebvre, Heather, Strahan, Ava , Rugo, H. S., Ballman, K., Watson, M., Wen, Y., Leon-Ferre, R., Niazi, Kayvan , Symmans, W. F., Carey, L. A., Li, Z., Stover, D. G., Gatti-Mays, Margaret Elena , Rugo, H. S., Ballman, K., Watson, M. A., Leon‐Ferre, Roberto A. , Niazi, K., Symmans, W. Fraser , AbdulJabbar, Khalid , Li, Zihai

Mayo Clinic

Clinical Cancer Research | February 20, 2026 | Volume: 32 | Issue: 4_Supplement | Pages: PS2-07-27-PS2-07-27

10.1158/1557-3265.sabcs25-ps2-07-27 Get It

Abstract Background: Stromal tumor infiltrating lymphocytes (sTILs) are associated with improved response to chemotherapy and better overall survival (OS) in triple-negative breast cancer (TNBC). Quantification of sTILs via hematoxylin and eosin (H&E) tumor slides offers a widely available method to define a simple, effective surrogate for host anti-tumor immunity. Digitization of H&E slides has rapidly gained acceptance for use in diagnostic pathology and research, opening the door for image-based computational approaches to enumerate sTILs, among other features. Methods: We describe QuTILs - a multilayer perceptron-based framework to detect/enumerate TILs trained on &gt;700,000 cells via The Cancer Genome Atlas Program (TCGA) slide images, implemented in the widely used open-source QuPath digital pathology suite. QuTILs was applied to digital H&E images using standard computing in primary breast tumors from phase 3 breast cancer clinical trials - CALGB 40502 (testing), CALGB 40601 and 40603 (validation) - in total 1,729 total images from 962 unique patients. The aims of this investigation were: 1) to assess the relationship between TIL patterns with overall or event-free survival outcomes; 2) to benchmark diverse image-based characteristics of TIL abundance and spatial architecture; and 3) to evaluate the association between image-based TIL levels and RNA-seq-based immune deconvolution metrics (CIBERSORT, EPIC, quanTIseq). Results: QuTILs average processing time was 7.9 minutes for whole-slide total TIL count and area density on a standard laptop workstation. In CALGB 40502, there was positive but modest correlation between pathologist TILs and QuTILs total TILs %, higher in the TNBC subgroup of CALGB 40502 (Pearson r = 0.55). In Cox proportional hazards models, the CALGB 40502 TNBC cohort showed significant univariate association for total TILs % with increasing decile (higher total TIL%) associated with reduced hazard (hazard ratio [HR]: 0.712, 95% CI: 0.559-0.906; P = 0.006), which remained significant in multivariable model incorporating age, race, and treatment arm (HR: 0.713, 95% CI: 0.556-0.915; P = 0.008). In validation TNBC clinical trial CALGB 40603, marginal TILs % was significant in the univariable Cox model (HR: 0.786, 95% CI: 0.639-0.966). Evaluation of TILs % by QuTILs with RNAseq-based deconvolution metrics in cohort-stratified and deconvolution method-stratified multivariable models showed that decile total TILs % by QuTILs was shown to significantly predict outcome in the EPIC (HR: 0.668, 95% CI: 0.466-0.957) and quanTIseq (HR: 0.646, 95% CI: 0.446-0.936) sets, with a similar magnitude as in clinical Cox, suggesting that RNA-based deconvolution estimates may not supplement the prognostic power of image-based TIL estimates. Exploratory analyses of pre- versus post-neoadjuvant therapy H&E images in CALGB 40603 and CALGB 40601 revealed a significant decrease in QuTILs total TIL% in CALGB 40603 for all pairs (n = 118 pairs, pre-median=9.52%, post-median=6.33%; Wilcoxon signed rank P &lt; 0.001) but no significant change in QuTILs total TIL% among all pairs in CALGB 40601 (n = 82 pairs, pre-median=15.92%, post-median=15.10%; P = 0.886). Conclusions: QuTILs provides a computationally efficient open-source workflow for sTIL identification from digital H&E images that can be deployed on a standard laptop. We present the first evaluation of digital sTIL enumeration in CALGB 40502, CALGB 40603, and CALGB 40601 phase III breast cancer clinical trials and demonstrate significant prognostic association with QuTIL total TIL % among TNBCs across studies. Citation Format: M. Vater, R. Salgado, E. Blige, H. Lefebvre, A. Strahan, M. Gatti-Mays, H. Rugo, K. Ballman, M. Watson, Y. Wen, R. Leon-Ferre, K. Niazi, W. Symmans, L. Carey, K. AbdulJabbar, Z. Li, D. Stover. Qutils: open-source image-based infiltrating immune cell detection and outcomes in calgb 40502, calgb 40603, and calgb 40601 phase iii breast cancer clinical trials [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2025; 2025 Dec 9-12; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2026;32(4 Suppl):Abstract nr PS2-07-27.
Variation in Lipid Management for Atherosclerotic Cardiovascular Disease Across US Health Systems
Shah, Nishant , Peterson, Eric D. , Shrader, Peter, Shoji, Satoshi , Freeman, Nikki , Martin, Seth S., Allred, Clint, Fernandez, S. A., Chamberlain, Alanna M., Arnold, Jonathan , Shapiro, Michael D., Priest, Elisa L. , Syed, Mahanaz, Kirchner, H. Lester , Leja, Monika, Kalich, Bethany , Jin, Ran , Navar, Ann Marie, Peterson, Eric D. , Chamberlain, Alanna M. , Arnold, Jonathan , Shah, Nishant P , Martin, Seth S , Fernandez, Soledad , Chamberlain, Alanna M , Shapiro, Michael D , Effron, Mark B , Syed, Mahanaz , Kirchner, H Lester , Kalich, Bethany , Jin, Ran , Wojcik, Cezary , Navar, Ann Marie , Shrader, Peter, Martin, Seth S. , Ahmad, Zahid , Jones, Laney K , Návar, Ann Marie

Mayo Clinic

Circulation: Population Health and Outcomes | February 20, 2026 | Volume: 19 | Issue: 4 | Pages: No page available

10.1161/circoutcomes.125.012622 | PMID 41717695 Get It

BACKGROUND: While health systems have implemented resources to improve lipid management in people with atherosclerotic cardiovascular disease, the population-level effectiveness is unclear. METHODS: Electronic health record data from patients with atherosclerotic cardiovascular disease between January 1, 2021, and December 31, 2023, across 16 US academic health systems were analyzed. Atherosclerotic cardiovascular disease (defined by diagnosis and procedure codes) was established on or before the index date defined as the date of the most recent LDL-C (low-density lipoprotein-cholesterol) or the last day of the study period for those without an LDL-C available. Systems were surveyed to identify lipid management programs (eg, prevention/lipid clinic, electronic health record–based tools, and lipid management algorithms). Sequential multilevel multivariable logistic regression modeling was used to (1) assess the system-level association between an LDL-C <70 mg/dL and the presence of lipid management programs, adjusting for patient-level demographic and clinical characteristics, and (2) whether system-level uptake of statin or nonstatin lipid-lowering therapy was associated with an LDL-C <70 mg/dL. RESULTS: We included 1 738 042 patients with atherosclerotic cardiovascular disease (median, 88 365 per system; range, 17 086–2 48 371). About 81% of the health systems had prevention or lipid clinics. The proportion of those on statins ranged from 31.0% to 60.4% across health systems (median, 46.3%). Lower proportions were observed in the use of high-intensity statins (16.2%–33.1%), nonstatins (2.6%–8.1%), and combination lipid-lowering therapy (1.7%–6.3%). Among those with an LDL-C level available (n=890 521), 42.5% had an LDL-C <70 mg/dL, ranging 35.8% to 49.4% across systems. There was no association between the odds of achieving LDL-C <70 mg/dL and health system lipid management algorithm, prevention clinics/lipid clinics, or electronic health record–based tools. Neither system-level high-intensity statin utilization nor nonstatin use was associated with an LDL-C <70 mg/dL. CONCLUSIONS: Despite variability in lipid management resources and lipid-lowering therapy use across systems, many did not reach an LDL-C <70 mg/dL, and there was low uptake of lipid-lowering therapy. Innovative implementation strategies are needed for system-level lipid management.
Incremental changes to improve outcomes in ALL
Litzow, Mark R., Litzow, Mark R. , Litzow, Mark R.

Mayo Clinic

Blood | February 19, 2026 | Volume: 147 | Issue: 8 | Pages: 801-802

10.1182/blood.2025031878 | PMID 41712294 Get It